Therapeutic Treatment

Abstract

The present invention relates to a combination comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, hereafter “Compound (I)”, and a taxane. Taxanes include established cancer drugs such as docetaxel (Taxotere™) and paclitaxel (Taxol™). Such combinations may be useful in the treatment or prophylaxis of cancer. The invention also relates to a pharmaceutical composition comprising such Compound (I) and a taxane. The invention further relates to a method of treatment comprising the simultaneous, sequential or separate administration of Compound (I) and a taxane, to warm-blooded animal, such as man. The invention also relates to a kit comprising Compound (I) and a taxane, optionally with instructions for use.

1 - 23 . (canceled) 
     
     
         24 . A kit comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, and a taxane. 
     
     
         25 . The kit according to  claim 24  wherein the taxane is selected from docetaxel, paclitaxel, cabazitaxel, larotaxel, ortataxel and tesetaxel. 
     
     
         26 . The kit according to  claim 25  wherein the taxane is selected from docetaxel and paclitaxel. 
     
     
         27 . The kit according to  claim 24  further comprising instructions for treating cancer in a patient in need of such treatment by administering the (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide to the patient, or a pharmaceutically acceptable salt thereof, and administering the taxane to the patient. 
     
     
         28 . The kit according to  claim 27  wherein the instructions are for treating breast cancer. 
     
     
         29 . The kit according to  claim 28  wherein the instructions state that the taxane is to be administered only within the 1 day prior to the first dosing of the (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide within a given dosage cycle. 
     
     
         30 . The kit according to  claim 29  wherein the dosage cycle involves (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide being administered for 3-4 consecutive days and not being administered for the other days within a dosage cycle of 6 to 9 days in length. 
     
     
         31 . The kit according to  claim 29  wherein the instructions state that the taxane is to be administered at 50-140 mg/m 2  of patient surface area on the day(s) when it is administered. 
     
     
         32 . The kit according to  claim 29  wherein the instructions state that the (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide is to be administered to the patient at 200-500 mg per day on the days when it is administered.